BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The company's core programs consist of Disc/Spine Program and Metabolic Program. Disc/Spine Program consists of cell therapy candidate, brtxDISC(TM) is a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow. Metabolic Program consists of ThermoStem(R), developing an allogeneic cell-based therapy to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. BioRestorative Therapies, Inc. is based in Melville, New York.
| Revenue (Most Recent Fiscal Year) | $0.40M |
| Net Income (Most Recent Fiscal Year) | $-8.98M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 33.59 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.14 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -3093.61% |
| Net Margin (Trailing 12 Months) | -3093.61% |
| Return on Equity (Trailing 12 Months) | -129.47% |
| Return on Assets (Trailing 12 Months) | -86.02% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.24 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.24 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.82 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.56 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.36 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.47 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 7.50M |
| Free Float | 5.59M |
| Market Capitalization | $13.13M |
| Average Volume (Last 20 Days) | 0.03M |
| Beta (Past 60 Months) | 77.73 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 25.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 69.38% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |